Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

Utilizing transposase for stable clone establishment, CHIMERA BIOSCIENCE INC.’s method offers higher safety, stability, and yield compared to current mainstream antibiotic selection or lentiviral methods. This approach is highly suitable for peptide therapeutics, including recombinant proteins and antibody drugs. Through CHIMERA BIOSCIENCE INC.’s collaboration with Bora Biologics, the established stable clones can be transitioned to Bora Biologics for industrial-scale protein production.

CHIMERA BIOSCIENCE INC. also develops viral gene delivery systems for cell and gene therapies, including adenovirus-based transposase/CRISPR-Cas editing systems and industrial-grade manufacturing processes for adeno-associated virus (AAV).

For monoclonal antibody production, CHIMERA BIOSCIENCE INC. goes beyond traditional hybridoma technology. We can perform direct screening from B cells following antigen-induced immune responses. Alternatively, we can construct phage display libraries from antibody VAB fragments for direct screening against target antigens. Furthermore, this process can directly generate CHO cell lines to facilitate subsequent scale-up production, significantly shortening development timelines and reducing costs.

Other core expertise of CHIMERA BIOSCIENCE INC. includes CRISPR/Cas gene editing, recombineering systems based on homologous recombination principles, and phage display library construction and screening for the identification of peptide drug candidate leads.

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl